1191 ATG-021, a novel 2+1 CD3-based T cell engager (TCE) targeting GPRC5D, demonstrates potent in vivo anti-tumor efficacy with low cytokine release

Abstract

BackgroundMultiple myeloma (MM) is a malignant plasma-cell disorder that accounts for accounts for 1% of all cancers and 10% to 15% of all hematologic cancers. Primary refractory to treatment and...